Panic disorder (PD) is an anxiety disorder characterized by panic attacks and anticipatory anxiety. PD is relatively common; the lifetime prevalence is reported to be 1--3%.^[@bib1]^ According to a previous twin study, the heritability of PD is estimated to be 0.43,^[@bib2]^ which suggests that both genetic and environmental factors have a role in the pathogenesis of PD. To date, several studies that applied a candidate-gene approach have reported susceptibility genes of PD, but many of them have not been successfully replicated in subsequent studies.^[@bib3]^ Recently, a genome-wide association study (GWAS) of European ancestry identified single-nucleotide polymorphisms (SNPs) in the transmembrane protein 132D gene (*TMEM132D*) associated with PD.^[@bib4]^ This result was supported by a replication study and meta-analyses of European subjects, which confirmed that *TMEM132D* is a susceptibility gene of PD.^[@bib5],[@bib6]^ However, in a Japanese GWAS of PD, SNPs in *TMEM132D* did not show a positive association with PD.^[@bib7],[@bib8]^

We previously found associations between PD and human leukocyte antigen (HLA), especially the *HLA-B* and *HLA-DRB1* genes, based on pathway analyses using the results from our Japanese GWAS of PD.^[@bib8]^ HLA is the human version of the major histocompatibility complex, which presents endogenous antigens to CD8+ and CD4+ T cells. There is a great number of polymorphisms in the *HLA* genes. *HLA* genes have been reported to be involved in not only immune-related diseases^[@bib9]^ but also several psychiatric disorders.^[@bib10]^ We genotyped the *HLA-B* and *HLA-DRB1* genes, and confirmed that the frequency of *HLA-DRB1\*13:02* was significantly higher in PD patients than in healthy individuals (case positivity: 18.1%; control positivity: 11.5%; *P*=2.62×10^−5^; odds ratio (OR)=1.70).^[@bib11]^

Previous studies have reported that the genetic factors and clinical features of several *HLA*-associated diseases differ between *HLA* allele-positive and -negative patients. Narcolepsy, with and without cataplexy, was associated with *HLA-DQB1\*06:02*,^[@bib12]^ and the severity of narcolepsy without cataplexy was higher in *HLA-DQB1\*06:02-*positive patients than in *HLA-DQB1\*06:02*-negative patients.^[@bib12],[@bib13]^ *HLA-B\*51* was strongly associated with risk factors for Behçet's disease,^[@bib14]^ and a significant association between one SNP in the *ERAP1* locus was observed only in *HLA-B\*51-*positive patients.^[@bib14]^ Hence there is a possibility that the genetic backgrounds might differ in PD subjects with or without *HLA-DRB1\*13:02*. To account for these effects of *HLA* alleles, we focused on a candidate PD gene, *TMEM132D*, and investigated the SNPs in the *TMEM132D* region in both *HLA-DRB1\*13:02*-positive and -negative subjects. In this analysis, genotyping data for the SNPs were generated using the Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, USA). Inclusion criteria for quality control were SNP call rate \>0.95, Hardy--Weinberg equilibrium (HWE) test *P*\>0.001, and minor allele frequency (MAF)\>0.05. We defined 'gene region' as the region located 50 kb upstream to 50 kb downstream of *TMEM132D* (chr12: 129556271--130388212 (GRCh37/hg19)). The SNP genotype data were subdivided into two data sets, those of *HLA-DRB1\*13:02-*positive subjects (cases: *N*=103; controls: *N*=198) and those of *HLA-DRB1\*13:02-*negative subjects (cases: *N*=438; controls: *N*=1,341). An imputation analysis was also performed to evaluate the potential association of ungenotyped SNPs in the *TMEM132D* region of both subgroups. IMPUTE2 software^[@bib15]^ was used to estimate SNP genotypes using the reference data set from 1000 Genomes Phase 3 haplotypes.^[@bib15]^ We filtered out low-quality imputed SNPs by applying the following conditions: SNP call rate ⩾0.95, HWE test *P*\>0.0001, and probability of imputation certainty ⩾0.9. After filtering, a total of 8,070 SNPs remained for subsequent analysis. Using the genotype data of these SNPs, case--control association tests were performed to examine whether SNPs in *TMEM132D* showed an association with PD in each subgroup. We set the significance level after multiple testing correction to *α*=1.26×10^−5^, which was calculated from 0.05 divided by the number of SNPs (*N*=3,978) pruned by high linkage disequilibrium (LD; *r* ^2^\>0.8) with PLINK SNP pruning procedure (window size in SNPs=100, the number of SNPs to shift the window=1).^[@bib16]^

In the analysis of the *HLA-DRB1\*13:02*-negative subgroup, nine SNPs in the *TMEM132D* region showed significant associations, and SNP rs4759997 had the lowest *P* value (*P*=5.02×10^−6^, OR=1.50; [Table 1](#tbl1){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}). In contrast, these SNPs were found to have no association with PD in the *HLA-DRB1\*13:02*-positive group ([Table 1](#tbl1){ref-type="table"} and [Supplementary Figure 1](#xob1){ref-type="supplementary-material"}). To find other SNPs potentially associated with PD in the *HLA-DRB1\*13:02*-negative group, logistic regression analysis adjusting for the effect of rs4759997 was also performed. The analysis showed that none of the SNPs in the *TMEM132D* region had an association that reached the threshold level of significance, which suggested that the nominal associations of SNPs in this region were derived from LD with rs4759997 ([Supplementary Figure 2](#xob1){ref-type="supplementary-material"}).

A previous study identified two SNPs, rs7309727 and rs11060369, in *TMEM132D* as susceptibility variants for PD in populations of European ancestry.^[@bib4]^ The two SNPs were also associated with higher anxiety and larger amygdala volumes.^[@bib17]^ In addition, the risk genotype of rs11060369 was found to enhance *TMEM132D* mRNA expression in the brain.^[@bib4]^ These two SNPs identified in populations of European ancestry were located in intron 3 of *TMEM132D*, while the SNPs found in our study, rs4759997 and the surrounding SNPs with significant *P* values, were located in intron 1. The SNP with the lowest *P* value, rs4759997, was not in LD with either rs7309727 or rs11060369 in individuals of Japanese ancestry (Japanese; rs7309727, *r* ^2^=0.001; rs11060369, *r* ^2^=0.003), while in individuals of European ancestry, SNP rs4759997 had very low frequency (MAF=0.009) according to HapMap data.^[@bib18],[@bib19]^ In addition, imputation analysis revealed that the two SNPs, rs7309727 and rs11060369, were not associated with PD in *HLA-DRB1\*13:02*-negative Japanese subjects (rs7309727: case MAF=0.36, control MAF=0.39, *P*=0.124; rs11060369: case MAF=0.46, control MAF=0.46, *P*=0.826). Such results, showing that different SNPs in *TMEM132D* are associated with PD in individual populations, might be derived from differences in the LD structure between the populations of Japanese and European ancestry ([Supplementary Figure 3](#xob1){ref-type="supplementary-material"}). Therefore, targeted resequencing of this gene is required in a future study.

Our study provides initial evidence that SNPs in *TMEM132D* show significant associations with PD in a *HLA-DRB1\*13:02*-negative group of Japanese individuals. Specifically, *TMEM132D* might affect PD in *HLA-DRB1\*13:02-*negative individuals. Further replication studies in independent and larger *HLA*-typed population samples are required to confirm these associations.
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![Results of the *HLA-DRB1\*13:02*-negative subgroup analysis in the *TMEM132D* region. Physical positions are based on GRCh37/hg19. The blue line represents the significance threshold (*α*=1.26×10^−5^).](hgv20161-f1){#fig1}

###### SNPs with *P*-value \<10^−4^ in the *TMEM132D* region

  *Position*[a](#t1-fn1){ref-type="fn"}       *SNP*     *HLA-DRB1\*13:02 negative*   *HLA-DRB1\*13:02 positive*                                                                            
  --------------------------------------- ------------- ---------------------------- ---------------------------- ----------------------------------------- ------ ------- ------- ------- ------
  130185851                                 rs1567509   0.283                        0.210                        1.01×10^−5^ [b](#t1-fn2){ref-type="fn"}   1.49   0.211   0.203   0.820   1.05
  130186374                                 rs7311162   0.279                        0.205                        5.87×10^−6^ [b](#t1-fn2){ref-type="fn"}   1.50   0.199   0.198   0.975   1.01
  130187014                                 rs264463    0.105                        0.064                        4.79×10^−5^                               1.73   0.050   0.054   0.854   0.93
  130187283                                 rs1397504   0.281                        0.208                        6.92×10^−6^ [b](#t1-fn2){ref-type="fn"}   1.49   0.199   0.200   0.989   1.00
  130187566                                 rs264464    0.104                        0.063                        5.30×10^−5^                               1.73   0.050   0.054   0.854   0.93
  130188352                                 rs264465    0.105                        0.063                        4.19×10^−5^                               1.73   0.058   0.061   0.908   0.96
  130188504                                 rs7962650   0.279                        0.206                        7.32×10^−6^ [b](#t1-fn2){ref-type="fn"}   1.49   0.194   0.200   0.876   0.97
  130189452                                rs67208922   0.104                        0.063                        5.46×10^−5^                               1.72   0.050   0.054   0.833   0.92
  130189478                                 rs264468    0.104                        0.063                        5.46×10^−5^                               1.72   0.050   0.054   0.833   0.92
  130189868                                rs10773696   0.279                        0.206                        8.65×10^−6^ [b](#t1-fn2){ref-type="fn"}   1.49   0.194   0.200   0.876   0.97
  130190130                                 rs7312812   0.279                        0.207                        1.19×10^−5^ [b](#t1-fn2){ref-type="fn"}   1.48   0.194   0.199   0.888   0.97
  130190285                                 rs1510820   0.279                        0.207                        9.10×10^−6^ [b](#t1-fn2){ref-type="fn"}   1.48   0.194   0.200   0.876   0.97
  130191111                                 rs7132791   0.279                        0.207                        9.10×10^−6^ [b](#t1-fn2){ref-type="fn"}   1.48   0.194   0.200   0.876   0.97
  130191332                                 rs264472    0.104                        0.063                        5.90×10^−5^                               1.72   0.050   0.056   0.745   0.88
  130191567                                 rs2398467   0.104                        0.063                        5.90×10^−5^                               1.72   0.049   0.056   0.725   0.87
  130191851                                rs529395389  0.104                        0.063                        6.92×10^−5^                               1.71   0.049   0.056   0.716   0.87
  130192489                                 rs588761    0.104                        0.063                        5.90×10^−5^                               1.72   0.049   0.056   0.716   0.87
  130193038                                 rs4759997   0.282                        0.208                        5.02×10^−6^ [b](#t1-fn2){ref-type="fn"}   1.50   0.199   0.200   0.989   1.00
  130193940                                 rs663071    0.104                        0.064                        9.67×10^−5^                               1.69   0.049   0.056   0.716   0.87
  130195133                                rs67408383   0.104                        0.063                        6.03×10^−5^                               1.72   0.049   0.056   0.716   0.87
  130195225                                 rs7304093   0.279                        0.208                        1.31×10^−5^                               1.47   0.194   0.200   0.876   0.97
  130199905                                 rs6486497   0.356                        0.286                        8.73×10^−5^                               1.38   0.257   0.293   0.356   0.84
  130201128                                rs10744430   0.366                        0.292                        3.19×10^−5^                               1.41   0.277   0.296   0.630   0.91
  130210550                                rs76801035   0.055                        0.027                        9.36×10^−5^                               2.07   0.025   0.020   0.738   1.21

Abbreviations: MAF, minor allele frequency; OR, odds ratio; PD, panic disorder; SNP, single-nucleotide polymorphism.

Physical position (according to GRCh37/hg19).

The significance level after multiple testing correction was set as *α*=1.26×10^−5^.
